Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):754–757. doi: 10.1038/bjc.1990.372

LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.

M Ferrarini 1, E Ferrero 1, C Fortis 1, A Poggi 1, M R Zocchi 1
PMCID: PMC1971538  PMID: 1700922

Abstract

Both lymphokine activated killer (LAK) cells and specific cytotoxic T lymphocytes appear to play a role in tumour immunity. Tumour infiltrating lymphocytes (TIL) which display a CD56+ phenotype (both CD3+ and CD3-) are also likely to possess anti-tumour activity. We have previously described a 120 kDa surface antigen, termed LAK1, expressed on a subset of human peripheral blood lymphocytes (20-50%) with both NK and LAK activity. The aim of the present study was to determine whether LAK1 antigen is able to distinguish among TIL two populations of effector cells displaying either specific or non MHC-restricted (NK/LAK) activity. We showed that about 25% of freshly derived TIL were weakly stained with anti-LAK1 monoclonal antibody and most of them were also CD3+ CD56-. After culture in recombinant interleukin-2 the majority of TIL were CD3+ CD56- and the percentage of LAK1+ cells increased up to 50%. Among cloned TIL, only those lacking LAK1 antigen displayed a specific cytotoxicity against the autologous tumour, whereas the non-lytic clones were able to produce both tumour necrosis factor and gamma-interferon. Moreover, when TIL from a renal cell carcinoma were fractionated into LAK1- and LAK1+ populations, the specific lytic activity was mainly evident when LAK1- lymphocytes were used as effector cells. Conversely, LAK activity was confined to the LAK1+ subset.

Full text

PDF
754

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belldegrun A., Muul L. M., Rosenberg S. A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988 Jan 1;48(1):206–214. [PubMed] [Google Scholar]
  2. Borst J., van de Griend R. J., van Oostveen J. W., Ang S. L., Melief C. J., Seidman J. G., Bolhuis R. L. A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature. 1987 Feb 19;325(6106):683–688. doi: 10.1038/325683a0. [DOI] [PubMed] [Google Scholar]
  3. Chong A. S., Scuderi P., Grimes W. J., Hersh E. M. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol. 1989 Mar 15;142(6):2133–2139. [PubMed] [Google Scholar]
  4. Colotta F., Bersani L., Lazzarin A., Poli G., Mantovani A. Rapid killing of actinomycin D-treated tumor cells by human monocytes. II. Cytotoxicity is independent of secretion of reactive oxygen intermediates and is suppressed by protease inhibitors. J Immunol. 1985 May;134(5):3524–3531. [PubMed] [Google Scholar]
  5. Henney C. S. Quantitation of the cell-mediated immune response. I. The number of cytolytically active mouse lymphoid cells induced by immunization with allogeneic mastocytoma cells. J Immunol. 1971 Dec;107(6):1558–1566. [PubMed] [Google Scholar]
  6. Itoh K., Platsoucas C. D., Balch C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988 Oct 1;168(4):1419–1441. doi: 10.1084/jem.168.4.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Melioli G., Merli A., Ferrini S., Mingari M. C., Moretta L. Phenotypic and functional heterogeneity of human T cell clones producing gamma-interferon. Ric Clin Lab. 1985 Jan-Mar;15(1):47–52. doi: 10.1007/BF03029161. [DOI] [PubMed] [Google Scholar]
  8. Moretta A., Pantaleo G., Moretta L., Mingari M. C., Cerottini J. C. Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations. J Exp Med. 1983 Aug 1;158(2):571–585. doi: 10.1084/jem.158.2.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Muul L. M., Spiess P. J., Director E. P., Rosenberg S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987 Feb 1;138(3):989–995. [PubMed] [Google Scholar]
  10. Ramarli D., Fox D. A., Reinherz E. L. Selective inhibition of interleukin 2 gene function following thymocyte antigen/major histocompatibility complex receptor crosslinking: possible thymic selection mechanism. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8598–8602. doi: 10.1073/pnas.84.23.8598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981 Apr;126(4):1614–1619. [PubMed] [Google Scholar]
  12. Whiteside T. L., Heo D. S., Takagi S., Herberman R. B. Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes. Transplant Proc. 1988 Apr;20(2):347–350. [PubMed] [Google Scholar]
  13. Zocchi M. R., Bottino C., Ferrini S., Moretta L., Moretta A. A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function. J Exp Med. 1987 Aug 1;166(2):319–326. doi: 10.1084/jem.166.2.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zocchi M. R., Poggi A., Mariani S., Gianazza E., Rugarli C. Identification of a new surface molecule expressed by human LGL and LAK cells production of a specific monoclonal antibody and comparison with other NK/LAK markers. Cell Immunol. 1989 Nov;124(1):144–157. doi: 10.1016/0008-8749(89)90118-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES